60 Degrees Pharmaceuticals, Tufts Medical Center Sign Patent License Deal Over Potential Babesiosis Treatment

MT Newswires Live

Dec 23, 2024

60 Degrees Pharmaceuticals (SXTP) and Tufts Medical Center said Monday that they signed a patent license agreement to jointly advance development and commercialization of tafenoquine for the treatment and prevention of babesiosis.

Under the deal, the companies with co-own patent applications related to tafenoquine for babesiosis, while 60 Degrees will hold exclusive global rights to commercialize the product and Tufts will receive royalties on net sales.

60 Degrees said it is the sponsor of a trial evaluating tafenoquine in treating severe babesiosis, for which enrollment is ongoing. The study's main study endpoints are the time to sustained clinical resolution of symptoms and time to molecular cure as determined by an FDA-approved nucleic acid test, according to the company.

Price: 1.17, Change: -0.10, Percent Change: -7.54

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2493076502"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2493076502\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2493076502?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-23 22:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2493076502","market":"sg","top_or_hot":-1,"title":"60 Degrees Pharmaceuticals, Tufts Medical Center Sign Patent License Deal Over Potential Babesiosis Treatment","media":"MT Newswires Live","content":"<html><body><p> 60 Degrees Pharmaceuticals (SXTP) and Tufts Medical Center said Monday that they signed a patent license agreement to jointly advance development and commercialization of tafenoquine for the treatment and prevention of babesiosis.</p><p>Under the deal, the companies with co-own patent applications related to tafenoquine for babesiosis, while 60 Degrees will hold exclusive global rights to commercialize the product and Tufts will receive royalties on net sales.</p><p>60 Degrees said it is the sponsor of a trial evaluating tafenoquine in treating severe babesiosis, for which enrollment is ongoing. The study's main study endpoints are the time to sustained clinical resolution of symptoms and time to molecular cure as determined by an FDA-approved nucleic acid test, according to the company.</p><p>Price: 1.17, Change: -0.10, Percent Change: -7.54</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>60 Degrees Pharmaceuticals, Tufts Medical Center Sign Patent License Deal Over Potential Babesiosis Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n60 Degrees Pharmaceuticals, Tufts Medical Center Sign Patent License Deal Over Potential Babesiosis Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-12-23 22:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> 60 Degrees Pharmaceuticals (SXTP) and Tufts Medical Center said Monday that they signed a patent license agreement to jointly advance development and commercialization of tafenoquine for the treatment and prevention of babesiosis.</p><p>Under the deal, the companies with co-own patent applications related to tafenoquine for babesiosis, while 60 Degrees will hold exclusive global rights to commercialize the product and Tufts will receive royalties on net sales.</p><p>60 Degrees said it is the sponsor of a trial evaluating tafenoquine in treating severe babesiosis, for which enrollment is ongoing. The study's main study endpoints are the time to sustained clinical resolution of symptoms and time to molecular cure as determined by an FDA-approved nucleic acid test, according to the company.</p><p>Price: 1.17, Change: -0.10, Percent Change: -7.54</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2493076502","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2493076502","pubTimestamp":1734964746,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"60 Degrees Pharmaceuticals  and Tufts Medical Center said Monday that they signed a patent license agreement to jointly advance development and commercialization of tafenoquine for the treatment and prevention of babesiosis.Under the deal, the companies with co-own patent applications related to tafenoquine for babesiosis, while 60 Degrees will hold exclusive global rights to commercialize the product and Tufts will receive royalties on net sales.60 Degrees said it is the sponsor of a trial evaluating tafenoquine in treating severe babesiosis, for which enrollment is ongoing. The study's main study endpoints are the time to sustained clinical resolution of symptoms and time to molecular cure as determined by an FDA-approved nucleic acid test, according to the company.Price: 1.17, Change: -0.10, Percent Change: -7.54","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","SXTP":"60 degrees pharmaceuticals, Inc."},"translate_title":"60 Degrees Pharmaceuticals与塔夫茨医疗中心签署潜在巴贝斯虫病治疗专利许可协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SXTP":0.9},"content_text":"60 Degrees Pharmaceuticals (SXTP) and Tufts Medical Center said Monday that they signed a patent license agreement to jointly advance development and commercialization of tafenoquine for the treatment and prevention of babesiosis.Under the deal, the companies with co-own patent applications related to tafenoquine for babesiosis, while 60 Degrees will hold exclusive global rights to commercialize the product and Tufts will receive royalties on net sales.60 Degrees said it is the sponsor of a trial evaluating tafenoquine in treating severe babesiosis, for which enrollment is ongoing. The study's main study endpoints are the time to sustained clinical resolution of symptoms and time to molecular cure as determined by an FDA-approved nucleic acid test, according to the company.Price: 1.17, Change: -0.10, Percent Change: -7.54","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}